Overview

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

Status:
Completed
Trial end date:
2007-05-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Tavaborole